

This is an abridged prospectus containing salient features of the Red Herring Prospectus (the “RHP”). You are encouraged to read greater details available in the RHP. Link to download RHP: <https://sheelbiotech.com/ipo/>

THIS ABRIDGED PROSPECTUS CONSISTS OF SEVEN (7) PAGES. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES.



Please scan this QR code to view the RHP



**SHEEL BIOTECH LIMITED**  
CIN: U24239DL1991PLC046531

REGISTERED OFFICE		CORPORATE OFFICE	CONTACT PERSON	EMAIL & TELEPHONE	WEBSITE		
8 Balaji Estates, 2nd Floor, Block-C, Guru Ravidas Marg, Kalkaji, South Delhi, New Delhi, India, 110019		N.A.	Mr. Anupam Pandey Company Secretary & Compliance Officer	<a href="mailto:compliance@sheelbiotech.com">compliance@sheelbiotech.com</a> & +91 88511 - 89801	<a href="http://www.sheelbiotech.com/">www.sheelbiotech.com/</a>		
NAME OF PROMOTER(S) OF THE COMPANY							
DR. SATYA NARAYAN CHANDAK, DR. SANJAY CHANDAK, MR. DIVYE CHANDAK, MRS. MINI CHADHA, M/S SATYA NARAYAN CHANDAK (HUF), M/S SANJAY CHANDAK (HUF) AND M/S SUMEET CHANDAK (HUF)							
DETAILS OF OFFER TO PUBLIC, PROMOTERS/ SELLING SHAREHOLDERS							
Type of Issue (Fresh/ OFS/ Fresh & OFS)	Fresh Issue Size (by no. of shares or by amount in Rs)	OFS Size (by no. of shares)	Total Issue Size (by no. of shares or by amount in Rs)	Issue Under 6(1)/ 6(2)	Share Reservation		
					QIB including Anchor	NII	Individual Investor
Fresh Issue	54,00,000 Equity Share of Face Value of Rs. 10/- each aggregating up to Rs. [●] lakhs.	NIL	54,00,000 Equity Share of Face Value of Rs. 10/- each aggregating up to Rs. [●] lakhs	The Offer is being made pursuant to Regulation 229(2) of SEBI (ICDR) Regulations, 2018.	Not more than 25,50,000 Equity Shares	Not more than 7,74,000 Equity Shares	Not more than 18,04,000 Equity Shares
These equity shares are proposed to be listed on Emerge Platform NSE Limited.							
OFS: Offer for Sale							
Price Band, Minimum Bid Lot & Indicative Timelines							
Price Band*				Rs. 59/- per Equity Share to Rs. 63/- per Equity Share			
Minimum Bid Lot Size				4,000 Equity Shares			
Bid/Offer Open On				September 30, 2025			
Bid/Offer Closes On				October 03, 2025			
Finalisation of Basis of Allotment				On or before October 06, 2025			
Initiation of Refunds				On or before October 07, 2025			
Credit of Equity Shares to Demat accounts of Allottees				On or before October 07, 2025			
Commencement of trading of Equity Shares				On or before October 08, 2025			
*For details of price band and basis of offer price, please refer to pre-issue advertisement and Red Herring Prospectus (RHP).							
Details of WACA of all shares transacted over the trailing twelve months from the date of RHP:							
Period	Name of Promoters/ Selling Shareholders	Weighted Average Cost of Acquisition (in Rs.)	Upper End of the Price Band is 63“X” times the WACA	Range of acquisition price: Lowest Price 59 - Highest Price 63 (in Rs.)			
Trailing Twelve Month from the date of RHP	Satya Narayan Chandak	NIL	NIL	Lowest Price:0, Highest Price: 0			
	Sanjay Chandak	NIL	NIL	Lowest Price:0, Highest Price: 0			
	Divye Chandak	NIL	NIL	Lowest Price:0, Highest Price: 0			
	Mini Chadha	NIL	NIL	Lowest Price:0, Highest Price: 0			
	Satya Narayan Chandak (HUF)	NIL	NIL	Lowest Price:0, Highest Price: 0			
	Sumeet Chandak (HUF)	NIL	NIL	Lowest Price:0, Highest Price: 0			
	Sanjay Chandak (HUF)	NIL	NIL	Lowest Price:0, Highest Price: 0			
WACA: Weighted Average Cost of Acquisition shall be calculated on fully diluted basis for the trailing twelve months from the date of RHP.							
This being the first public issue of our Company, there has been no formal market for the Equity Shares. The face value of our Equity Shares is ₹ 10 each and the Floor Price and Cap Price are 5.9 times and 6.3 times of the face value of the Equity Shares, respectively. The Floor Price, Cap Price and Issue Price (determined and justified by our Company in consultation with the Book Running Lead Manager as stated in “Basis for Issue Price” on page 133 of this Red Herring Prospectus) should not be taken to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares or regarding the price at which the Equity Shares will be traded after listing.							

GENERAL RISKS								
Investments in Equity and Equity related securities involve a degree of risk and investors should not invest any funds in this issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the Red Herring Prospectus. Specific attention of the investors is invited to the section “Risk Factors” beginning on page 28 of this Red Herring Prospectus.								
PROCEDURE								
You may obtain a physical copy of the Bid-cum-Application Form and the RHP from the stock exchange, syndicate members, registrar to the issue, share transfer agents, depository participants, stockbrokers, underwriters, bankers to the issue, investors’ associations or Self Certified Syndicate Banks.								
If you wish to know about processes and procedures applicable to this issue, you may request for a copy of the RHP and/or the General Information Document (GID) from the BRLM’s or download it from the websites of the Stock Exchange i.e. <a href="https://www.nseindia.com/">https://www.nseindia.com/</a> and the BRLMs i.e., <a href="http://www.narnolia.com">www.narnolia.com</a> .								

## PRICE INFORMATION OF BOOK RUNNING LEAD MANAGERS

### Narnolia Financial Services Limited

S. No.	Issuer Name	Issue Size (Rs. in Cr.)	Issue Price (Rs.)	Listing Date	Opening Price on Listing Date	+/-% change in closing price, +/-% change in closing benchmark]- 30th calendar days from listing	+/-% change in closing price, +/-% change in closing benchmark]- 90th calendar days from listing	+/-% change in closing price, +/-% change in closing benchmark]- 180th calendar days from listing
Initial Public Offering - Main Board								
N.A.								
Initial Public Offering – SME Exchange								
1.	Divyadhan Recycling Industries Limited	24.17	64	October 04, 2024	84.00	0.00% (2.84) %	(14.23%) (3.30%)	(50.54%) (6.73%)
2.	Pranik Logistics Limited	22.47	77	October 17, 2024	79.00	0.06% (4.92) %	(6.90%) (6.36%)	(4.92%) (5.74%)
3.	Usha Financial Services Limited	98.44	168	October 31, 2024	164.00	(28.63) % (0.31) %	(39.12%) (4.31%)	(56.59%) 0.54%
4.	Sat Kartar Shopping Limited	33.80	81	January 17, 2025	153.90	23.46 % (0.12) %	(9.42%) 2.79%	19.56% 8.66%
5.	Mayasheel Ventures Limited	27.28	47	June 27, 2025	58.00	(5.52%) (2.89%)	N.A.	N.A.
6.	Ace Alpha Tech Limited	32.22	69	July 03, 2025	81.00	51.57 % (3.07) %	N.A.	N.A.
7.	Adcounty Media India Limited	50.69	85	July 04, 2025	130.00	(11.81) % (2.78) %	N.A.	N.A.
8.	Shree Refrigerations Limited	117.32	125	August 01, 2025	169.86	29.64 % (0.44) %	N.A.	N.A.
9.	Cash Ur Drive Marketing Limited	54.73	130	August 05, 2025	155.00	(4.90) % 0.04 %	N.A.	N.A.
10.	Anondita Medicare Limited	69.50	145	September 01, 2025	275.50	N.A.	N.A.	N.A.

\* Disclosures subject to recent 10 issues (Initial Public offerings) in current financial year and two preceding financial years managed by each Merchant Banker with common issues disclosed once.

<b>Name of BRLMs and contact details (telephone and email id) of each BRLM</b>	<b>Narnolia Financial Services Limited</b> <b>Address:</b> 201, 2 <sup>nd</sup> Floor, Marble Arch, 236 B A.J.C Bose Road, Kolkata, West Bengal- 700020, India <b>Tel.:</b> 033-40501500;   <b>Email:</b> <a href="mailto:ipo@narnolia.com">ipo@narnolia.com</a>   <b>Website:</b> <a href="http://www.narnolia.com">www.narnolia.com</a> <b>Contact Person:</b> Mr. Rajveer Singh <b>SEBI Registration No.:</b> INM000010791
<b>Name of Syndicate Member(s)</b>	NEXGEN Financial Solutions Private Limited

<b>Name of the Market Maker and contact details (telephone and email)</b>	<b>Mansi Share Stock Broking Private Limited</b> <b>Address:</b> Avirahi Building, 201 B, S. V. Road, Behind Adidas Showroom, Borivali (W), Mumbai,
---	--

id) of each Market Maker	Maharashtra, India, 400092 Tel No: 02240503870 Email Id: <a href="mailto:compliance@mansishares.in">compliance@mansishares.in</a> Contact Person: Mr. Deep Paresh Shah SEBI Registration No.: INZ000247433
Name of Registrar to the Issue and contact details (telephone and email id)	<b>Skyline Financial Services Private Limited</b> Address: D-153 A, 1 <sup>st</sup> Floor, Okhla Industrial Area, Phase - I, New Delhi-110020 Telephone: +91-11-40450193-97 Email: <a href="mailto:compliances@skylinerta.com">compliances@skylinerta.com</a> Website: <a href="http://www.skylinerta.com">www.skylinerta.com</a> Contact Person: Mr. Anuj Rana SEBI Registration Number: INR000003241 CIN: U74899DL1995PTC071324
Name of Statutory Auditor	<b>Shyam Sunder Mangla &amp; Co LLP.</b> Address: SCO- 201, Shopping Centre, Sector-08, Faridabad- 121006. Tel No.: 0129 – 2247275 Fax No.: 0129 – 2240625 Email Id: <a href="mailto:rajatmangla@ssmangla.co.in">rajatmangla@ssmangla.co.in</a> Contact Person: Rajat Mangla Firm Registration No.: 009633N/N500055
Name of Peer Review Auditor	<b>M/s Rajan K Gupta &amp; Co LLP, Chartered Accountants</b> Address: 2nd Floor, Corporate Suites, 34, Ansal Plaza, Sector 1, Vaishali, Ghaziabad – 201010 Tel No.: 01204552353 Fax No.: N.A. Email Id: <a href="mailto:rajan@carajangupta.com">rajan@carajangupta.com</a> Contact Person: Rajan Gupta Firm Registration No.: 005945C/C400352
Name of Credit Rating Agency and the rating or grading obtained, if any	Not Applicable
Name of Debenture trustee, if any.	Not applicable
Self-Certified Syndicate Banks	The lists of banks that have been notified by SEBI to act as SCSB for the Applications Supported by Blocked Amount (ASBA) Process are provided on the website of SEBI. For details on Designated Branches of SCSBs collecting the Bid Cum Application Forms, please refer to the below mentioned SEBI link <a href="https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes">https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes</a>
Non-Syndicate Registered Brokers	You can submit Application Forms in the Issue to Non-Syndicate Registered Brokers at the Non-Syndicate Broker Centers. For further details, see section titled “Issue Procedure” beginning at page no. 368 of the Red Herring Prospectus
Details regarding website address(es)/ link(s) from which the investor can obtain list of registrar to issue and share transfer agents, depository participants and stock brokers who can accept application from investor (as applicable)	The details of the Designated Registrar and Share Transfer Agents Locations and Designated Collecting Depository Participant Locations, along with their names and contact details are available on the website of the Emerge platform of NSE Limited (NSE Emerge) ( <a href="https://www.nseindia.com/">https://www.nseindia.com/</a> ) and updated from time to time.

PROMOTERS OF THE ISSUER COMPANY			
S. No.	Name	Individual/ Corporate	Experience & Educational Qualification
1.	Mr. Satya Narayan Chandak	Individual	<b>Dr. Satya Narayan Chandak, aged 75, is the Chairman and Director of our Company.</b> He was appointed as the Additional Director of our Company on August 22, 2024. Further, he was redesignated as the Chairman of our Company w.e.f August 28, 2024. He has a Doctorate Degree in June 2013 from The Open International University, Columbo, Sri Lanka. He has done his M.Com from University of Rajasthan in the year 2007. In the year 1979, he has passed Banking oriented examination from The Indian Institute of Bankers (now known as Indian Institute of Banking and Finance). Further, has obtained LLB from University of Lucknow in 1978. He has done his B.com from University of Rajasthan in the year 1969. He has been member of Delhi Advisory Panel of Central Board of Film certification, Ministry of Information and Broadcasting in 1995. Also, he has been awarded ‘Rajeev Gandhi National Unity Award’ in 1994. He has 34 years of vast experience working in the fields of Agriculture, Biotechnology, Tissue Culture, Horticulture, Floriculture, landscaping, Organic Adoption and Certification & Protected cultivation along with the banking sector, dairy production sector, and Publication and release of Books. Along with above, he guides the Company towards managing the finance, optimum utilization of budget, cost effective local procurement and executing policies and programs of government for the benefit of farmers.
2.	Mr. Sanjay Chandak	Individual	<b>Sanjay Chandak, aged 53, is Promoter and Executive Director of the Company.</b> He was appointed as Executive Director of the Company w.e.f., August 14, 2024. He has Doctorate Degree from California Public University, USA in Business Administration. He has 27 years of vast experience in Bio-technology, Tissue Culture, Floriculture, Seed, Organic Adoption, and Certification & Protected cultivation. His focus is on sourcing technologies from various parts of India and abroad and forming tie-ups with organisations for expansion of our business.
3.	Mr. Divye Chandak	Individual	<b>Mr. Divye Chandak, aged 28 years, is Promoter and Managing Director of the Company.</b> He was appointed as Executive Director of the Company w.e.f. August 22, 2024. Subsequently his designation was changed to Managing Director for a period of 5 years by special resolution of shareholders in an Extra-ordinary General Meeting held on August 28, 2024. He has done Bachelor in Chemical Engineering from University of Manchester, UK. Further, he has qualified PG program in

			Management from Institute of Management Technology, Ghaziabad. He has 7 years of experience in the fields of Marketing and Business Development. He looks after the marketing department in our organization. He has significantly enhanced Sheel Biotech's operations by optimizing project efficiency through strategic planning, resource allocation, and effective time management. He successfully managed budgets to ensure financial stability, formed strategic partnerships to drive business growth, and contributed to sales and marketing efforts to meet revenue targets. His efforts in securing key partnerships and implementing business strategies have expanded the company's market reach and increased revenue.
4.	Ms. Mini Chadha	Individual	<b>Ms. Mini Chadha, aged 56 years, holds a position of Non-Executive Director in the company.</b> She has Master's Degree from Delhi University. She has vast experience in public speaking, mentorship. She was appointed as a Director of the Company w.e.f., August 22, 2024. She has played a pivotal role in Sheel Biotech's growth by guiding corporate social responsibility (CSR). Her leadership has fostered impactful CSR programs that benefit employees, farmers, and communities, aligning business success with social responsibility. Through philanthropy and charity, she has strengthened stakeholder relationships and ensured the company's growth is shared with society, creating a positive and sustainable impact.

For details about the "Our Promoter", "Our Promoter Group", please refer to Page No. 271 and 280 respectively of the Red Herring Prospectus.

BUSINESS OVERVIEW AND STRATEGY	
Company Overview:	Our Company, Sheel Biotech Limited (hereinafter referred to as "SBL" or "Our Company") was incorporated as a private limited company with the name of "Sheel Biotech Private Limited" under the Companies Act, 1956 vide certificate of incorporation dated November 26, 1991, issued by that time Registrar of Companies, Delhi & Haryana, bearing Registration no - 046531. Further, our company was converted into a Public Limited Company in pursuance of a special resolution passed by the members of our Company at the Extra- Ordinary General Meeting held on December 30, 1992 & name of our Company changed from "Sheel Biotech Private Limited" to "Sheel Biotech Limited" & Registrar of Companies, Delhi & Haryana has issued a new certificate of incorporation consequent upon conversion dated April 02, 1992, bearing CIN: U24239DL1991PLC046531.
Product/Service Offering: Revenue Segmentation by Product/Service Offering	We have five business segments: 1. Tissue Culture Segment 2. Organic Segment 3. Planting & Landscaping Segment 4. Skill & FPO Segment 5. Green & Packhouse Segment For details regarding "Segment wise revenue break-up", please refer to chapter titled "Our Business" on Page no. 171 of the Red Herring Prospectus.
Geographies Served: Revenue Segmentation by Geographies	For details regarding "Geographical wise revenue break-up", please refer to chapter titled "Our Business" on Page no. 171 of the Red Herring Prospectus.
Key Performance Indicators:	For details regarding "Key Performance Indicators" refer to Chapter – "Basis for Issue Price" on Page no. 133 of the Red Herring Prospectus.
Client Profile or Industries Served: Revenue Segmentation in terms of top 5/10 Client or Industries	For details regarding "Our Client Profiles and Revenue Segmentation" refer to Chapter – "Our Business" on Page no. 171 respectively of the Red Herring Prospectus.
Intellectual Property, if any:	As on the date of Red Herring Prospectus, we have six (6) Intellectual property right registered in our name. For details refer to Chapter – "Our Business" on Page no. 171 of the Red Herring Prospectus.
Market Share:	Not ascertainable
Manufacturing Plant, if any:	As on the date of Red Herring Prospectus, we do not have Manufacturing Plant. For details refer to Chapter – "Our Business" on Page no. 171 of the Red Herring Prospectus.
Employee Strength:	As on September 12, 2025, we have 160 permanent employees. For details see "Our Business" on page 171 of the Red Herring Prospectus.

Note: (1) The quantitative statements shall be substantiated with Key Performance Indicators (KPIs) and other quantitative factors.

(2) No qualitative statements shall be made which cannot be substantiated with KPIs.

(3) Information provided in the table should not exceed 1000 words.

BOARD OF DIRECTORS				
S. No.	Name	Designation	Experience & Educational Qualification	Other Directorships
1.	Mr. Satya Narayan Chandak	Chairman & Director	<b>Experience:</b> He has 34 years of diverse experience across Agriculture, Biotechnology, Tissue Culture, Horticulture, Floriculture, Organic Certification, Protected Cultivation, Banking, Dairy, and Publications. He also guides the Company in finance management, budget optimization, cost-effective procurement, and implementing government programs for farmers' benefit <b>Educational Qualification:</b> Ph. D in Business Management	<b>Indian Private Companies</b> Blue Ocean Realestates Private Limited <b>Indian Public Companies</b> Nil <b>Section 8 Companies</b> Nil <b>Indian LLPs</b> Nil <b>Partnership Firm</b> Nil
2.	Dr. Sanjay Chandak	Director	<b>Experience:</b> He has 27 years of experience in Biotechnology, Tissue Culture, Floriculture, Seed, Organic Certification, and Protected Cultivation, with a focus on sourcing technologies and building partnerships for business expansion.	<b>Indian Private Companies</b> Nil <b>Indian Public Companies</b> Nil <b>Section 8 Companies</b>

			<b>Educational Qualification:</b> Ph. D In Business Administration	Nil <b>Indian LLPs</b> Nil <b>Partnership Firm</b> Nil
3.	Mr. Divye Chandak	Managing Director	<b>Experience:</b> He has 7 years of experience in the fields of Marketing and Business Development.  <b>Educational Qualification:</b> Bachelor in Chemical Engineering, PG program in Management	<b>Indian Private Companies</b> Jayshee Investments Private Limited <b>Indian Public Companies</b> Nil <b>Section 8 Companies</b> Nil <b>Indian LLPs</b> Nil
4.	Mrs. Mini Chadha	Director	<b>Experience:</b> She has 2 years of experience in public speaking, mentorship. <b>Educational Qualification:</b> M.ed	<b>Indian Private Companies</b> Nil <b>Indian Public Companies</b> Nil <b>Section 8 Companies</b> Nil <b>Indian LLP</b> Nil
5.	Mr. Ramesh Chandra Srivastava	Independent Director	<b>Experience:</b> He has 47 years of rich experience in research management, having worked with ICAR-VPKAS, Almora (Uttarakhand) and ICAR-IIWM, Bhubaneswar. <b>Educational Qualification:</b> Doctrate in Philosophy	<b>Indian Private Companies</b> Nil <b>Indian Public Companies</b> Nil <b>Section 8 Companies</b> Nil <b>Indian LLPs</b> Nil
6.	Mr. Shyamsundar Bang	Independent Director	<b>Experience:</b> He has 24 Years of Experience and also associated with Jubilant group for over 24 years. He is currently appointed as Chairman of FICCI Committee for Task Force on Manufacturing Excellence Member of Governing Council of Indian National Academy of Engineering. <b>Educational Qualification:</b> M. Tech	<b>Indian Private Companies</b> Nil <b>Indian Public Companies</b> 1. Jubilant Beverages Limited 2. Jubilant Bevco Limited <b>Section 8 companies</b> Nil <b>Indian LLPs</b> Nil
7.	Mr. Atul Kumar	Independent Director	<b>Experience:</b> He has 36 years of rich experience in Finance <b>Educational Qualification:</b> MBA in Finance	<b>Indian Private Companies</b> Nil <b>Indian Public Companies</b> Nil <b>Section 8 Companies</b> Nil <b>Indian LLP</b> Nil

For further details, please refer chapter titled "Our Management" on Page No. 248 of the Red Herring Prospectus.

## OBJECTS OF THE ISSUE

### DETAILS OF MEANS OF FINANCE

The following table sets forth details of the Net Proceeds:

S. No.	Particulars	Amount in Lakh
1.	Gross Issue Proceeds	[●]*
2.	Less: Issue Related Expenses	[●]**
	<b>Net proceeds</b>	<b>[●]*</b>

\*Subject to finalization of basis of allotment.

\*\*As per the certificate given by M/s Shyam Sunder Mangla & Co. LLP, Chartered Accountants, dated September 10, 2025, the Company has incurred Rs. 22.95 Lakhs towards issue expenses as on September 09<sup>th</sup>, 2025. 22,94,998 (Twenty-Two Lakhs Ninety-Four Thousand Nine Hundred and Ninety-Eight) Lakhs towards issue expenses from April 01, 2024 till September 09, 2025.

We propose to deploy the Net Proceeds for the previously mentioned purposes in accordance with the estimated schedule of implementation and deployment of funds set forth in the table below.

(Amount in Lakhs)				
S. No.	Particulars	Amount to be funded from Net Proceeds	Expenses incurred till March 31, 2025	Estimated Utilisation of Net Proceeds (F.Y. 2025-26)
1.	Capital Expenditure Requirement	911.95	[●]	911.95
2.	Working Capital Requirement	1,588.00	[●]	1,588.00
3.	General Corporate Purposes*	[●]	[●]	[●]
4.	Issue Expense	[●]	[●]	[●]



\*The amount utilized for general corporate purposes shall not exceed 15% of the Gross Proceeds or Rs. 10 crores, whichever is lower.

The objects detailed above are intended to be funded from the proceeds of the Issue while any remaining funding needs will be met through the company's internal accruals. Accordingly, we confirm that there is no requirement for us to make firm arrangements of finance through verifiable means towards at least 75% of the stated means of finance, excluding the amount to be raised from the proposed Issue.

The fund requirement and deployment are based on internal management estimates and have not been appraised by any bank or financial institution. These are based on current conditions and are subject to change in light of changes in external circumstances or costs, other financial conditions, business or strategy, as discussed further below.

Details and reasons for non -deployment or delay in deployment of proceeds or changes in utilization of issue proceeds of past public issues/rights issue, if any, of the Company in the preceding 10 years: Not Applicable

Name of monitoring agency, if any: Our Company has appointed a Monitoring Agency naming CARE Ratings Limited on a voluntary basis for monitoring the utilization of Gross Proceeds.

Terms of Issuance of Convertible Security, if any:

Convertible securities being offered by the Company	Not Applicable
Face Value / Issue Price per Convertible securities	
Issue Size	
Interest on Convertible Securities	
Conversion Period of Convertible Securities	
Conversion Price for Convertible Securities	
Conversion Date for Convertible Securities	
Details of Security created for CCD	

#### Shareholding Pattern:

Sr. No.	Particulars	Pre-Issue number of shares	% Holding of Pre issue
1.	Promoter and Promoter Group	1,45,02,250	96.99%
2.	Public	450,300	3.01%
<b>Total</b>		<b>1,49,52,550</b>	<b>100.00%</b>

Shareholding Pattern: For more details, please refer to "Capital Structure" on page no.75 of the RHP.

#### RESTATED FINANCIALS OF OUR COMPANY

On the basis of restated standalone financial statements

(Amount in Lakhs)

Particulars	For the Year ended 31 <sup>st</sup> March 2025	For the Year ended 31 <sup>st</sup> March 2024	For the Year ended 31 <sup>st</sup> March 2023
Share Capital	1,495.26	414.37	414.37
Reserve & Surplus	6,890.16	6,858.15	5,939.78
Net Worth	8,385.42	7,272.52	6,354.15
Revenue from operation	10,175.25	9,228.22	8,011.57
Profit after Tax	1,063.61	1,050.97	507.65
EPS Basic and Diluted (in Rs.)	7.21	7.25	3.50
NAV per Equity Share (in Rs.)	56.84	50.15	43.81
<b>Total borrowings</b>			
- Long Term	482.25	1,026.81	944.14
- Short Term	1,253.87	1,327.15	972.95
ROE/ RoNW	13.59%	15.38%	8.24%

#### INTERNAL RISK FACTORS

The below mentioned risks are top 5 risk factors as per the RHP.

1. We depend on government tenders for our revenue of operations. Any unavailability or any failure to secure these tenders in the future may adversely affect our business operations and financial conditions.
2. One of our business segment Tissue culture demands the highest level of precautions in quality, storage, and temperature management. Any negligence in these areas can significantly affect our business outcomes.
3. We use the proper techniques in the whole tissue culture process. Any Ineffective sterilization of tools and media can lead to contamination, which would adversely affect the entire culture.
4. Our business is subject to seasonal fluctuations that could result in delays or disruptions to our operations during the critical periods of our projects and cause severe damage to our premises and equipments.
5. Our Company is involved in certain legal proceedings/litigations. Any adverse decision in such proceedings may render us/ them liable to penalties and may adversely affect our business and result of operations.

For further details, please refer chapter titled "Risk Factors" on page no. 28 of the RHP.

#### SUMMARY OF OUTSTANDING LITIGATIONS, CLAIMS AND REGULATORY ACTION

- A. Total Number of outstanding litigations involving our company and our promoter involved:

Name	Criminal Proceedings	Tax Proceedings	Statutory or regulatory actions	Civil Proceedings	Other Material litigations	Aggregate amount involved*
<b>Company</b>						
By	5	Nil	Nil	5	-	36.47
Against	3	9	Nil	10	-	148.54
<b>Promoter</b>						
By	Nil	Nil	Nil	Nil	-	Nil
Against	Nil	5	2	Nil	-	2.04
<b>Director/KMP</b>						
By	1	Nil	Nil	Nil	-	Nil
Against	Nil	1	Nil	5	-	18.79
<b>Subsidiary</b>						
By	-	-	-	-	-	-
Against	-	-	-	-	-	-
<b>Group Companies</b>						
By	-	-	-	-	-	-
Against	-	2	-	-	-	127.02

\*To the extent quantifiable.

For details of the said case refer chapter titled “Outstanding Litigations and material Developments” beginning on page 317 of this Red Herring Prospectus

**B. Brief Details of top 5 Material outstanding litigation against the Company and Amount involved:**

S. No.	Particulars	Litigation Filed by	Current Status	Amount Involved (Rs.)
1.	The Show Cause Notice dated 23.05.2024 u/s 73 of the CGST/ SGST Act	GST Authority	Pending	Rs. 39,39,246/-
2.	The present criminal case has been filed under Section 420 and 406 of Indian Penal Code, 1860 alleging that the Respondents supplied low quality poly bag banana tissue culture plants to the Complainant, with the intention of defrauding and cheating the Complainant	Balram Singh Yadav	Pending	Rs. 20,00,000 (Rupees The Twenty Lakhs) only.
3.	The present consumer complaint is filed alleging that Respondent 1 supplied 6,200 poly bag banana tissue culture were of inferior quality and failed to develop or produce bananas.	Balram Singh Yadav	Pending	Rs. 19,99,000/- (Nineteen Lakhs and Ninety-Nine Thousand) and Rs. 5,00,000 (Five Lakhs only) for harassment and mental agony
4.	EA/3/2022, Parasram Jhamnani vs. Sheel Biotech Limited, before District Consumer Disputes Redressal Forum, Kota, Rajatshan	Parasram Jhamnani	Pending	Rs.19,81,000/- (Rupees Nineteen Lakh Eighty-One Thousand only).
5.	An outstanding Demand was issued u/s 153C of Income Tax Act, 1961 issued against Sh. Shyam Sundar Bang, for which an Appeal has been accepted by the Income Tax Appellate Tribunal (ITAT), New Delhi Appeal bearing no. ITA 1887/ Del/2023.	CBDT	Pending	Rs. 18,79,810/- (Rupees Eighteen Lakh Seventy-Nine Thousand Eight Hundred and Ten only).

C. Regulatory Action, if any - disciplinary action taken by SEBI or stock exchanges against the Promoters in last 5 financial years including outstanding action, if any: None

D. Brief details of outstanding criminal proceedings against Promoters: NA

**ANY OTHER INFORMATION AS PER LEAD MANAGER / ISSUER COMPANY – NIL**

**DECLARATION BY THE COMPANY**

We, hereby declare that, all the relevant provisions of the Companies Act, 2013 and the guidelines/regulations issued by the Government of India or the guidelines/regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities Exchange Board of India Act, 1992, as the case may be, have been complied with no statement made in the Red Herring Prospectus is contrary to the provisions of Companies Act, 2013, the Securities and Exchange Board of India Act, 1992 or rules made there under or regulations/guidelines issued, as the case may be. We further certify that all the statements made in the Red Herring Prospectus are true and correct.

*This page intentionally left blank*